+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Dynavax Technologies Corporation - logo

Dynavax is a clinical-stage biopharmaceutical company with multiple product candidates in development for the treatment of autoimmune and inflammatory diseases, and the treatment of cancer. The company’s lead product candidates include HEPLISAV-B, an investigational adult hepatitis B vaccine; and AZD1419, which is in Phase II clinical trial for the treatment of asthma. Dynavax Technologies Corporation was founded in 1996 and is headquartered in Berkeley, California.

Immunotherapy Drugs Market - Global Outlook & Forecast 2021-2026 - Product Thumbnail Image

Immunotherapy Drugs Market - Global Outlook & Forecast 2021-2026

  • Report
  • October 2021
  • 210 Pages
  • Global
From
Global Hepatitis B Therapeutics Market 2022-2026 - Product Thumbnail Image

Global Hepatitis B Therapeutics Market 2022-2026

  • Report
  • April 2022
  • 120 Pages
  • Global
From
Vaccine Sales Market Report 2023-2033 - Product Thumbnail Image

Vaccine Sales Market Report 2023-2033

  • Report
  • June 2023
  • 364 Pages
  • Global
From
From
Hepatitis Drugs Global Market Report 2023 - Product Thumbnail Image

Hepatitis Drugs Global Market Report 2023

  • Report
  • March 2023
  • 200 Pages
  • Global
From
From
Hepatitis B Vaccines - Global Strategic Business Report - Product Thumbnail Image

Hepatitis B Vaccines - Global Strategic Business Report

  • Report
  • September 2023
  • 182 Pages
  • Global
From
From
Oligonucleotide Therapy Global Market Report 2023 - Product Thumbnail Image

Oligonucleotide Therapy Global Market Report 2023

  • Report
  • February 2023
  • 250 Pages
  • Global
From
Loading Indicator